Transcriptional dysregulation in Huntington's disease - PubMed

Review

Transcriptional dysregulation in Huntington's disease

J H Cha. Trends Neurosci. 2000 Sep.

Abstract

Although the gene responsible for Huntington's disease was discovered in 1993, the pathogenic mechanisms by which mutant huntingtin causes neuronal dysfunction and death remain unclear. However, increasing evidence suggests that mutant huntingtin disrupts the normal transcriptional program of susceptible neurons. Thus, transcriptional dysregulation might be an important pathogenic mechanism in Huntington's disease.

Similar articles

• Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis.

  Kumar A, Vaish M, Ratan RR. Kumar A, et al. Drug Discov Today. 2014 Jul;19(7):956-62. doi: 10.1016/j.drudis.2014.03.016. Epub 2014 Mar 21. Drug Discov Today. 2014. PMID: 24662036 Free PMC article. Review.

• Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.

  Stanek LM, Yang W, Angus S, Sardi PS, Hayden MR, Hung GH, Bennett CF, Cheng SH, Shihabuddin LS. Stanek LM, et al. J Huntingtons Dis. 2013;2(2):217-28. doi: 10.3233/JHD-130057. J Huntingtons Dis. 2013. PMID: 25063516

• Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.

  Truant R, Atwal RS, Burtnik A. Truant R, et al. Prog Neurobiol. 2007 Nov;83(4):211-27. doi: 10.1016/j.pneurobio.2006.11.004. Epub 2007 Jan 22. Prog Neurobiol. 2007. PMID: 17240517 Review.

• Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.

  Valencia A, Reeves PB, Sapp E, Li X, Alexander J, Kegel KB, Chase K, Aronin N, DiFiglia M. Valencia A, et al. J Neurosci Res. 2010 Jan;88(1):179-90. doi: 10.1002/jnr.22184. J Neurosci Res. 2010. PMID: 19642201

• [The role of mitochondria in the pathogenesis of Huntington's disease].

  Karachitos A, Gałgańska H, Kmita H. Karachitos A, et al. Postepy Biochem. 2010;56(2):174-81. Postepy Biochem. 2010. PMID: 20873112 Review. Polish.

Cited by

• Therapeutic Strategies in Huntington's Disease.

  Kanazawa I. Kanazawa I. J Clin Neurol. 2006 Dec;2(4):213-24. doi: 10.3988/jcn.2006.2.4.213. Epub 2006 Dec 20. J Clin Neurol. 2006. PMID: 20396523 Free PMC article.

• Huntington disease models and human neuropathology: similarities and differences.

  Vonsattel JP. Vonsattel JP. Acta Neuropathol. 2008 Jan;115(1):55-69. doi: 10.1007/s00401-007-0306-6. Epub 2007 Nov 3. Acta Neuropathol. 2008. PMID: 17978822 Free PMC article. Review.

• Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

  Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Rodriguez-Lebron E, et al. Mol Ther. 2005 Oct;12(4):618-33. doi: 10.1016/j.ymthe.2005.05.006. Mol Ther. 2005. PMID: 16019264 Free PMC article.

• Hippo Signaling Pathway Dysregulation in Human Huntington's Disease Brain and Neuronal Stem Cells.

  Mueller KA, Glajch KE, Huizenga MN, Wilson RA, Granucci EJ, Dios AM, Tousley AR, Iuliano M, Weisman E, LaQuaglia MJ, DiFiglia M, Kegel-Gleason K, Vakili K, Sadri-Vakili G. Mueller KA, et al. Sci Rep. 2018 Jul 27;8(1):11355. doi: 10.1038/s41598-018-29319-4. Sci Rep. 2018. PMID: 30054496 Free PMC article.

• Therapeutic approaches to Huntington disease: from the bench to the clinic.

  Caron NS, Dorsey ER, Hayden MR. Caron NS, et al. Nat Rev Drug Discov. 2018 Oct;17(10):729-750. doi: 10.1038/nrd.2018.133. Epub 2018 Sep 21. Nat Rev Drug Discov. 2018. PMID: 30237454 Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information